Vaccines for the prevention of cardiovascular disease.
Atherosclerosis, especially coronary heart disease (CHD), remains a most significant global public health problem. Highly effective LDL-lowering therapies have gained widespread adoption in the United States and throughout the developed world, but therapeutic options for raising low HDL, a key independent risk factor for CHD, remain limited. We are developing a vaccine approach to raising HDL, by inducing an immune response to endogenous cholesteryl ester transfer protein (CETP), and have demonstrated proof of principle in preclinical and clinical models. This vaccine approach may offer the opportunity to address low HDL with a cost-effective semi-annual injection.
Ryan
Una S
US
AVANT Immunotherapeutics, Inc., 119 Fourth Avenue, Needham, MA 02494, USA. uryan@avantimmune.com
Rittershaus
Charles W
CW
D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000737:chemistry / Q000276:immunology*; D008076:Cholesterol, HDL / Q000097:blood; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D011817:Rabbits; D016032:Randomized Controlled Trials as Topic; D014612:Vaccines / Q000627:therapeutic use*
D000906:Antibodies; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D010455:Peptides; D014612:Vaccines